Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Renal-Cell Carcinoma

Another Approval for Keytruda
Combining an immune checkpoint inhibitor and a tyrosine kinase inhibitor (TKI) significantly improved progression-free survival (PFS) in treatment-naïve patients with advanced renal-cell carcinoma (RCC) compared with a TKI alone.

Results 1 - 2 of 2